BEIGF:OTCMKTS
BeOne Medicines
US$21,95
0,00%
(0,00) 1D
9 ມິ.ຖ., 12 ໂມງ 49 ນາທີ 46 ວິນາທີ GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BEIGF...
Mkt. cap
43,04 ຕື້
Avg. vol.
0,00
Volume
0,00
52-wk high
US$24,92
52-wk low
US$21,95
Beta
0,84
Shares outstanding
1,43 ຕື້
No. of employees
12 ພັນ
Mkt. cap
43,04 ຕື້
Avg. vol.
0,00
Volume
0,00
52-wk high
US$24,92
52-wk low
US$21,95
Beta
0,84
Shares outstanding
1,43 ຕື້
No. of employees
12 ພັນ
News stories
From web sources and news partners
AD HOC NEWS
·
1 ມື້ກ່ອນ
RBC raises target for BeOne Medicines stock to USD 459.00
MarketBeat
·
1 ມື້ກ່ອນ
BeOne Medicines (NASDAQ:ONC) Stock Falls 5.8% - Here's What Happened
Profile
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
About BeOne Medicines
CEOJohn Vincent Oyler | John Vincent Oyler
Employees12 ພັນ
Founded28 ຕ.ລ. 2010
Headquarters-
SectorBiotechnology
Websitebeonemedicines.com